AGREEMENT AND PLAN OF REORGANIZATION by and among PROGENICS PHARMACEUTICALS, INC., PROGENICS PHARMACEUTICALS NEVADA, INC. UR LABS, INC. and SHAREHOLDERS OF UR LABS, INC. Dated as of December 22, 2005
by
and
among
PROGENICS
PHARMACEUTICALS, INC.,
PROGENICS
PHARMACEUTICALS NEVADA, INC.
UR
LABS,
INC.
and
SHAREHOLDERS
OF UR LABS, INC.
Dated
as
of December
22, 2005
TABLE
OF
CONTENTS
Page
ARTICLE
I
DEFINITIONS AND DEFINED TERMS
|
1 | |||
Section
1.1
|
Definitions
and Defined Terms
|
1 | ||
ARTICLE
II
PURCHASE OF ASSETS
|
2 | |||
Section
2.1
|
Purchase
and Sale of Transferred Assets
|
2 | ||
Section
2.2
|
Excluded
Assets
|
3 | ||
ARTICLE
III
ASSUMPTION OF LIABILITIES
|
3 | |||
Section
3.1
|
Assumed
Liabilities
|
3 | ||
Section
3.2
|
Retained
Liabilities
|
3 | ||
ARTICLE
IV
PURCHASE PRICE
|
4 | |||
Section
4.1
|
Purchase
Price
|
4 | ||
Section
4.2
|
Indemnification
Escrow
|
4 | ||
ARTICLE
V
CLOSING
|
5 | |||
Section
5.1
|
Closing
|
5 | ||
Section
5.2
|
Deliveries
at Closing
|
5 | ||
ARTICLE
VI
REPRESENTATIONS AND WARRANTIES OF SELLER AND THE
SHAREHOLDERS
|
8 | |||
Section
6.1
|
Organization
and Good Standing
|
9 | ||
Section
6.2
|
Authorization
and Effect of Agreement
|
9 | ||
Section
6.3
|
Consents
and Approvals; No Violations
|
10 | ||
Section
6.4
|
No
Third Party Options
|
10 | ||
Section
6.5
|
Permits;
Compliance with Law
|
10 | ||
Section
6.6
|
Litigation
|
10 | ||
Section
6.7
|
Assets
Necessary to Business; No Other Agreements
|
11 | ||
Section
6.8
|
Financial
Statements
|
11 | ||
Section
6.9
|
Absence
of Certain Changes
|
11 | ||
Section
6.10
|
No
Default
|
11 | ||
Section
6.11
|
Contracts
|
12 | ||
Section
6.12
|
Employees
|
12 | ||
Section
6.13
|
Title
to Assets
|
13 |
i
Section
6.14
|
Assignment
of Contracts
|
13 | ||
Section
6.15
|
Environmental
|
13 | ||
Section
6.16
|
No
Broker
|
13 | ||
Section
6.17
|
No
Misleading Statements
|
13 | ||
Section
6.18
|
Employee
Benefits
|
13 | ||
Section
6.19
|
Taxes
|
14 | ||
Section
6.20
|
Proprietary
Rights
|
15 | ||
Section
6.21
|
Ownership
|
15 | ||
Section
6.22
|
Business
|
15 | ||
Section
6.23
|
Entirely
for Own Account
|
16 | ||
Section
6.24
|
Disclosure
of Information
|
16 | ||
Section
6.25
|
Investment
Experience and Accredited Investor Status
|
16 | ||
Section
6.26
|
Restricted
Securities
|
16 | ||
Section
6.27
|
Legends
|
16 | ||
Section
6.28
|
Univertical
Transfer
|
17 | ||
ARTICLE
VII
REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER
|
17 | |||
Section
7.1
|
Corporate
Organization
|
17 | ||
Section
7.2
|
Authorization
and Effect of Agreement
|
18 | ||
Section
7.3
|
Consents
and Approvals; No Violations
|
18 | ||
Section
7.4
|
No
Broker
|
18 | ||
Section
7.5
|
SEC
Reports
|
19 | ||
Section
7.6
|
Financial
Statements
|
19 | ||
Section
7.7
|
Parent
Common Stock
|
19 | ||
ARTICLE
VIII
COVENANTS
|
20 | |||
Section
8.1
|
Access
|
20 | ||
Section
8.2
|
Notification
|
20 | ||
Section
8.3
|
No
Inconsistent Action
|
20 | ||
Section
8.4
|
Further
Assurances
|
20 | ||
Section
8.5
|
Transfer
Taxes
|
21 | ||
Section
8.6
|
Bulk
Sales Laws
|
21 | ||
Section
8.7
|
Confidentiality
|
21 | ||
Section
8.8
|
Non-Competition
|
21 | ||
Section
8.9
|
Market
Listing
|
21 |
ii
Section
8.10
|
Certain
Agreements
|
21 | ||
Section
8.11
|
Covenant
to Provide Legal Opinions
|
22 | ||
Section
8.12
|
Certain
Tax Matters
|
22 | ||
ARTICLE
IX
SURVIVAL; INDEMNIFICATION
|
22 | |||
Section
9.1
|
Survival
of Indemnification Rights
|
22 | ||
Section
9.2
|
Indemnification
Obligations
|
23 | ||
Section
9.3
|
Indemnification
Procedure
|
24 | ||
Section
9.4
|
Tax
Treatment of Indemnification
|
24 | ||
Section
9.5
|
Relation
of Indemnity to Escrow Shares
|
25 | ||
Section
9.6
|
Aggregate
Indemnification Liability
|
25 | ||
ARTICLE
X
MISCELLANEOUS PROVISIONS
|
25 | |||
Section
10.1
|
Notices
|
25 | ||
Section
10.2
|
Expenses
|
26 | ||
Section
10.3
|
Successors
and Assigns
|
27 | ||
Section
10.4
|
Extension;
Waiver
|
27 | ||
Section
10.5
|
Entire
Agreement
|
27 | ||
Section
10.6
|
Amendments,
Supplements, Etc
|
27 | ||
Section
10.7
|
Applicable
Law; Waiver of Jury Trial
|
28 | ||
Section
10.8
|
Actions
by Seller or the Shareholders
|
28 | ||
Section
10.9
|
Execution
in Counterparts
|
28 | ||
Section
10.10
|
Titles
and Headings
|
28 | ||
Section
10.11
|
Invalid
Provisions
|
29 | ||
Section
10.12
|
Publicity
|
29 | ||
Section
10.13
|
Specific
Performance
|
29 |
iii
Exhibits
Exhibit
A
- Definitions and Defined Terms
Exhibit
B
- Patents and Patent Applications
Exhibit
C
- Escrow Agreement
Exhibit
D
- Xxxx of Sale
Exhibit
E
- Assignment and Assumption Agreement
Exhibit
F
- Chicago License Assignment Agreement
Exhibit
G
- URL-Xxxxxxxx Consent and Assignment Agreement
Exhibit
H
- PGNX-URL Consent and Assignment Agreement
Exhibit
I
- Patent Assignment
Exhibit
J
- Registration Rights Agreement
Exhibit
K
- Cross Release
Annexes
Annex
2.1
- Balance Sheet and Income Statement
iv
This
AGREEMENT AND PLAN OF REORGANIZATION (this “Agreement”)
is
made and entered into as of December 22, 2005 by and among Progenics
Pharmaceuticals, Inc., a Delaware corporation (“Parent”),
Progenics Pharmaceuticals Nevada, Inc., a Nevada corporation (“Purchaser”);
UR
Labs, Inc., a Nevada corporation (“Seller”);
and
Xxxx X. Xxxxx, Xxxxx X. Xxxxx, and Xxxxx Xxxxx, Trustee of the Drell Family
Trust U/A dated 4/28/88, the shareholders of Seller (each a “Shareholder”
and,
collectively, the “Shareholders”).
RECITALS:
WHEREAS,
Seller is engaged in the business of pharmaceutical development and licensing
(the “Business”);
WHEREAS,
Seller wishes to transfer substantially all of its assets related to the
Business to Purchaser solely in exchange for 500,000 shares of Parent’s Common
Stock (as defined below) in a transaction intended to qualify as a
“reorganization” within the meaning of Section 368(a)(1)(C) of the Code, it
being contemplated by Seller and Parent that Seller will thereafter, as an
integral part of the transactions contemplated by this Agreement, distribute
the
shares of Parent to the Shareholders in complete liquidation of Seller and
dissolve Seller; and
WHEREAS,
certain parties hereto and others have executed a Cross Release dated the date
hereof relating to certain of the assets that are the subject of this Agreement,
which is attached as Exhibit
K
hereto.
NOW,
THEREFORE, in consideration of the mutual representations, warranties, covenants
and agreements herein contained, the parties hereto agree as
follows:
ARTICLE
I
DEFINITIONS
AND DEFINED TERMS
Section
1.1 Definitions
and Defined Terms.
Unless
the context otherwise requires or as otherwise defined herein, capitalized
terms
used in this Agreement shall have the meanings set forth in Exhibit
A
hereto.
ARTICLE
II
PURCHASE
OF ASSETS
Section
2.1 Purchase
and Sale of Transferred Assets.
On
the
terms and subject to the conditions set forth herein, at the Closing as
described in Article
V
hereto,
Seller shall, and the Shareholders shall cause Seller to, sell, transfer,
convey, assign and deliver to Purchaser, and Purchaser shall purchase and
acquire from Seller, good and valid title to, and all of Seller’s rights and
interests in, all of the rights, properties and assets used in or held for
use
in, necessary for or otherwise relating to the Business, other than the Excluded
Assets (collectively, the “Transferred
Assets”),
free
and clear of all Liens (other than Permitted Liens), including, without
limitation, good and valid title to, and all rights and interests in, the
following:
(a) All
assets reflected on the balance sheet as of April 30, 2005 relating to the
Business (the “Balance
Sheet”)
and
all assets used to generate revenue and income reflected on the summary of
operations statement relating to the Business for the year ended April 30,
2005
(the “Income
Statement”),
which
Balance Sheet and Income Statement are set forth in Annex
2.1(a),
other
than, in each case, assets disposed of after the date of such Balance Sheet
and
Income Statement and on or prior to the Closing in the ordinary course of
business consistent with past practice.
(b) All
assets used, or held for use in, necessary for or otherwise relating to the
Business acquired in the ordinary course of business consistent with past
practice after April 30, 2005 and on or prior to the Closing Date.
(c) All
Contracts relating to the Business, including, without limitation, the Chicago
License Agreement, the URL-Xxxxxxxx Agreement and the Exclusive Sub-License
Agreement.
(d) All
general intangibles and intangible property, including, without limitation,
all
Proprietary Rights and agreements relating thereto that are used or held for
use
in, necessary for or otherwise relating to the Business, including, without
limitation, all of Seller’s rights and goodwill included therein and in the
patents and patent applications listed in Exhibit
B
hereto.
(e) All
books
and records relating to the Chicago License Agreement, the URL-Xxxxxxxx
Agreement and the Exclusive Sub-License Agreement.
The
Contracts included in the Transferred Assets, including, without limitation,
those listed above, are hereinafter collectively referred to as the
“Assumed
Contracts.”
2
Section
2.2 Excluded
Assets. Notwithstanding
anything contained in this Agreement to the contrary, cash, bank deposits,
securities held in brokerage accounts, computers and office equipment located
in
the home of any Shareholder and any physical
inventory of Azaribine and its cogeners and derivatives (“Azaribine”),
the
lease for a storage facility in Carson City, NV and the contents of such storage
facility (collectively,
the
“Excluded
Assets”)
will
not be included in the Transferred Assets.
ARTICLE
III
ASSUMPTION
OF LIABILITIES
Section
3.1 Assumed
Liabilities.
At the
Closing, Parent and Purchaser will not assume or agree to undertake to pay,
satisfy, discharge or perform, and will not be deemed by virtue of the execution
and delivery of this Agreement or any document delivered at the Closing pursuant
to this Agreement, or as a result of the consummation of the transactions
contemplated by this Agreement, to have assumed, or to have agreed to pay,
satisfy, discharge or perform, any liability, obligation, indebtedness or Taxes
of Seller or of any other Person or in any way relating to the Business (whether
primary or secondary, direct or indirect, known or unknown, absolute or
contingent, matured or unmatured, or otherwise), other than, in the case of
the
Purchaser, the obligations and liabilities of Seller from and after the Closing
Date pursuant to the terms of the Assumed Contracts, to the extent, and only
to
the extent, that such Assumed Contracts are actually assigned to Purchaser
and
such liabilities and obligations relate to the period from and after the Closing
(the “Assumed
Liabilities”).
Section
3.2 Retained
Liabilities.
Notwithstanding anything contained in this Agreement to the contrary, Parent
and
Purchaser do not assume or agree or undertake to pay, satisfy, discharge or
perform, and will not be deemed by virtue of the execution and delivery of
this
Agreement or any document delivered at the Closing pursuant to this Agreement,
or as a result of the consummation of the transactions contemplated by this
Agreement, to have assumed, or to have agreed to pay, satisfy, discharge or
perform, any liability, obligation, indebtedness or Taxes of Seller or of any
other Person or in any way relating to the Business (whether primary or
secondary, direct or indirect, known or unknown, absolute or contingent, matured
or unmatured, or otherwise) other than, in the case of the Purchaser, the
Assumed Liabilities (such liabilities and obligations retained by Seller,
including, without limitation, (i) notes payable by Seller and any other
indebtedness of Seller, (ii) liability associated with the physical inventory
of
Azaribine, (iii) lease for storage facility in Carson City, NV, (iv) liability
associated with the contents of such storage facility, and all other liabilities
and obligations with respect to the Excluded Assets, being referred to herein
as
the “Retained
Liabilities”).
It is
specifically agreed that Seller shall remain liable for all of the Retained
Liabilities.
3
ARTICLE
IV
PURCHASE
PRICE
Section
4.1 Purchase
Price.
In
consideration of the conveyance to Purchaser of all right, title and interest
in
and to the Transferred Assets and the other rights granted to Parent and
Purchaser hereunder, and subject to the terms and conditions
hereof:
(a) Purchaser
shall, at Closing, assume the Assumed Liabilities; and
(b) Parent
shall, at Closing, pay an aggregate purchase price (the “Purchase
Price”)
of
500,000 shares of voting common stock, par value $0.0013 (“Common
Stock”),
of
Parent, adjusted in accordance with the terms of this Article
IV
and
Section
9.5
hereto,
as applicable, which shall be delivered by issuing and delivering a facsimile
of
the following stock certificates at Closing, and instructing the Company’s
transfer agent to deliver by overnight courier the original stock certificates
no later than two (2) Business Days following the date hereof:
(i) One
stock
certificate registered in the name of Seller representing 300,000 shares of
Common Stock (the “Closing
Date Shares”);
and
(ii) One
stock
certificate registered in the name of JPMorgan Chase Bank (the
“Escrow
Agent”),
as
nominee for the Seller, representing 200,000 shares of Common Stock (the
“Escrow
Shares”
and,
together with the Closing Date Shares, the “Shares”).
Section
4.2 Indemnification
Escrow.
The
Escrow Shares delivered to the Escrow Agent in accordance with Section
4.1(b)(ii)
shall be
held by the Escrow Agent and shall be paid in whole or in part in accordance
with the terms of the Escrow Agreement by and among Parent, Seller, the
Shareholders, the Shareholder Representative and the Escrow Agent attached
hereto as Exhibit
C
(the
“Escrow
Agreement”)
to:
(a) Purchaser
Indemnified Parties to the extent necessary to satisfy any obligation of the
Seller and the Shareholders pursuant to Article IX, and
(b) Seller
on
the date that is sixteen (16) months following the Closing Date, to the extent
that the remaining Escrow Shares, if any, exceed the maximum amount that could
reasonably be expected to be necessary to satisfy all claims by the Purchaser
Indemnified Parties asserted on or prior to such date pursuant to Article IX.
4
ARTICLE V
CLOSING
Section
5.1 Closing.
Upon the
terms and subject to the conditions of this Agreement, the closing of the
transactions contemplated by this Agreement (the “Closing”)
will
be coordinated from the offices of Purchaser’s counsel, on December 22, 2005 or
at such other time and place and on such other date as Purchaser and Seller
shall agree in writing (the “Closing
Date”);
provided that the effective time of the Closing shall be 12:01 a.m. of the
Closing Date.
Section
5.2 Deliveries
at Closing.
At the
Closing:
(a) Seller
shall, and the Shareholders shall cause Seller to, deliver or cause to be
delivered to Parent and/or Purchaser (as applicable) the following:
(i) the
Escrow Agreement, duly executed by Seller, the Shareholders and the Shareholder
Representative;
(ii) a
Xxxx of
Sale, duly executed by Seller, in substantially the form attached hereto as
Exhibit
D
(the
“Xxxx
of Sale”);
(iii) an
Assignment and Assumption Agreement, duly executed by Seller, in substantially
the form attached hereto as Exhibit
E
(the
“Assignment
and Assumption Agreement”);
(iv) Chicago
License Assignment Agreement to assign the Chicago License Agreement from Seller
to Purchaser, duly executed by Seller, in substantially the form attached hereto
as Exhibit
F
(the
“Chicago
License Assignment Agreement”);
(v) URL-Xxxxxxxx
Consent and Assignment Agreement, duly executed by Seller, in substantially
the
form attached hereto as Exhibit
G
(the
“URL-Xxxxxxxx
Consent and Assignment Agreement”);
(vi) PGNX-URL
Consent and Assignment Agreement to assign the Exclusive Sublicense Agreement
from Seller to Purchaser, duly executed by Seller, in substantially the form
attached hereto as Exhibit
H
(the
“PGNX-URL
Consent and Assignment Agreement”);
5
(vii) Patent
Assignment Agreement, duly executed by Seller, in substantially the form
attached hereto as Exhibit
I
(the
“Patent
Assignment Agreement”);
(viii) Registration
Rights Agreement, duly executed by the Seller and the Shareholders, in
substantially the form attached as Exhibit
J
hereto
(the “Registration
Rights Agreement”);
(ix) releases,
in form and substance reasonably satisfactory to Parent, evidencing discharge,
removal and termination of all Liens (other than Permitted Liens) to which
any
Transferred Assets being conveyed at the Closing are subject, which releases
shall be effective at or prior to the Closing;
(x) a
certificate, dated the Closing Date, duly executed by the President of Seller,
on behalf of Seller, certifying as to (a) the attached copy of the action by
unanimous written consent of the Board of Directors of Seller authorizing and
approving the execution, delivery and performance of, and the consummation
of
the transactions contemplated by, this Agreement and any other documents or
instruments contemplated hereby, and stating that the resolutions thereby
certified have not been amended, modified, revoked or rescinded, and (b) the
attached copy of the action by written consent of the Shareholders authorizing
and approving the execution, delivery and performance of, and the consummation
of the transactions contemplated by, this Agreement and any other documents
or
instruments contemplated hereby, and stating that the action thereby certified
has not been amended, modified, revoked or rescinded; and
(xi) such
other duly executed documents and certificates as may be required to be
delivered by Seller pursuant to the terms of this Agreement or as may be
reasonably requested by Parent prior to the Closing.
(b) The
Shareholders shall deliver, or cause to be delivered to Purchaser, the
following:
(i) the
Escrow Agreement, duly executed by the Shareholders and the Shareholder
Representative;
(ii) such
other duly executed documents and certificates as may be required to be
delivered by the Shareholders pursuant to the terms of this Agreement or as
may
be reasonably requested by Purchaser prior to the Closing.
6
(c) Parent
shall deliver, or cause to be delivered to Seller, the following:
(i) a
facsimile copy of the stock certificate, registered in the name of Seller,
representing the Closing Date Shares;
(ii) the
Escrow Agreement, duly executed by Parent and the Escrow Agent;
(iii) the
Xxxx
of Sale, duly executed by Purchaser;
(iv) the
Assignment and Assumption Agreement, duly executed by Purchaser;
(v) the
Registration Rights Agreement, duly executed by the Parent;
(vi) the
Chicago License Assignment Agreement, duly executed by Purchaser;
(vii) the
URL-Xxxxxxxx Consent and Assignment Agreement, duly executed by
Purchaser;
(viii) The
PGNX-URL Consent and Assignment Agreement, duly executed by
Purchaser;
(ix) The
Patent Assignment Agreement, duly executed by Purchaser;
(x) a
certificate, dated the Closing Date, duly executed by Parent, certifying as
to
the attached copy of the resolutions of the Board of Directors of Parent
authorizing and approving the execution, delivery and performance of, and the
consummation of the transactions contemplated by, this Agreement and any other
documents or instruments contemplated hereby, and stating that the action
thereby certified has not been amended, modified, revoked or
rescinded;
(xi) such
other duly executed documents and certificates as may be required to be
delivered by Parent or Purchaser pursuant to the terms of this Agreement or
as
may be reasonably requested by Seller prior to the Closing; and
7
(xii) a
certificate, dated the Closing Date, duly executed by Purchaser, certifying
as
to (a) the attached copy of the action by written consent of the Board of
Directors of Purchaser authorizing and approving the execution, delivery and
performance of, and the consummation of the transactions contemplated by, this
Agreement and any other documents or instruments contemplated hereby, and
stating that the action thereby certified has not been amended, modified,
revoked or rescinded and (b) the attached copy of the action by written consent
of the sole shareholder of Purchaser authorizing and approving the execution,
delivery and performance of, and the consummation of the transactions
contemplated by, this Agreement and any other documents or instruments
contemplated hereby, and stating that the action thereby certified has not
been
amended, modified, revoked or rescinded.
(d) Parent
shall deliver, or cause to be delivered to the Shareholders, the following
such
other duly executed documents and certificates as may be required to be
delivered by Parent or Purchaser pursuant to the terms of this Agreement or
as
may be reasonably requested by the Shareholders prior to the
Closing.
(e) Parent
and Seller shall deliver, or cause to be delivered to the Escrow Agent, the
following:
(i) The
Escrow Agreement duly executed by Parent, Seller, the Shareholders and the
Shareholder Representative; and
(ii) a
facsimile copy of the stock certificate representing the Escrow Shares, in
form
and substance reasonably satisfactory to Purchaser, Seller and the Escrow
Agent.
ARTICLE
VI
REPRESENTATIONS
AND WARRANTIES OF SELLER AND THE SHAREHOLDERS
Except
as
otherwise disclosed to Parent in a schedule delivered to Parent by Seller and
the Shareholders prior to the execution of this Agreement (with specific
reference to the representations and warranties in this Article
VI
to which
the information in such schedule relate) (the “Disclosure
Schedule”),
Seller and the Shareholders, jointly and severally, represent and warrant to
Parent and Purchaser as follows:
8
Section
6.1 Organization
and Good Standing.
Seller
is a corporation duly incorporated, validly existing and in good standing under
the Laws of the State Nevada and has all requisite corporate power and authority
to own, lease, operate and otherwise hold its properties and assets and to
carry
on its business (including, without limitation, the Business) as presently
conducted. Seller is duly qualified or licensed to do business as a foreign
corporation and is in good standing in every jurisdiction in which the nature
of
the business conducted by it (including, without limitation, the Business)
or
the assets or properties owned or leased by it requires qualification, except
where the failure to be so qualified, licensed or in good standing would not,
individually or in the aggregate, be reasonably likely to have a Material
Adverse Effect.
Section
6.2 Authorization
and Effect of Agreement.
Seller
has all requisite corporate power and Seller and the Shareholders have all
requisite legal authority to execute and deliver this Agreement and the
Collateral Agreements to which they are or are proposed to be a party and to
perform their respective obligations hereunder and under any such Collateral
Agreements. The execution and delivery of this Agreement and the Collateral
Agreements by Seller and the Shareholders and the performance by Seller and
the
Shareholders of their respective obligations hereunder and thereunder, as the
case may be, and the consummation by Seller and the Shareholders of the
transactions contemplated hereby and thereby, as the case may be, have been
duly
authorized by its Boards of Directors and all of the shareholders of the Seller,
in the case of Seller, and no other corporate or other action on the part of
any
of Seller or the Shareholders is necessary to authorize the execution and
delivery of this Agreement and the Collateral Agreements to which they are
or
are proposed to be a party or the consummation of the transactions to which
they
are or are proposed to be a party contemplated hereby or thereby. This Agreement
has been duly and validly executed and delivered by Seller and the Shareholders
and constitutes a legal, valid and binding obligation of Seller and the
Shareholders, enforceable against Seller and the Shareholders in accordance
with
its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium and similar laws affecting creditors’ rights and
remedies generally.
9
Section
6.3 Consents
and Approvals; No Violations.
No
filing with, and no Permit or Consent of any Governmental Authority or any
other
Person is necessary for consummation of the transactions contemplated by this
Agreement or any Collateral Agreements. Neither the execution and delivery
of
this Agreement or any Collateral Agreement by Seller or the Shareholders who
are
or are proposed to be a party nor the consummation by Seller or the Shareholders
of the transactions contemplated by this Agreement or any Collateral Agreement
to which they are or are proposed to be a party nor compliance by Seller or
the
Shareholders with any of the provisions hereto or thereto will (a) conflict
with
or result in any breach of any provision of the certificate of incorporation
or
by-laws of Seller, (b) result in a violation or breach of, or constitute (with
or without due notice or lapse of time or both) a default (or give rise to
any
right of termination, modification, cancellation or acceleration or loss of
material benefits) under, any of the terms, conditions or provisions of any
Contract to which Seller or any Shareholder is a party or may be subject or
which is included in the Transferred Assets or the Assumed Liabilities or (c)
violate any Permit or Law applicable to Seller or any Shareholder, the
Transferred Assets, the Assumed Liabilities or the Business, except in the
case
of clauses (b) or (c), for violations, breaches or defaults which would not,
individually or in the aggregate, be reasonably likely to have a Material
Adverse Effect.
Section
6.4 No
Third Party Options.
Except
for this Agreement, there are no existing agreements, options, commitments
or
other rights granting any Person the right to acquire Seller’s or any
Shareholder’s right, title or interest in or to any of the Transferred Assets or
any interest therein.
Section
6.5 Permits;
Compliance with Law.
(a) Seller
holds all Permits necessary for the lawful conduct of the Business under and
pursuant to all applicable Laws, except where the failure to hold any such
Permits would not, individually or in the aggregate, be reasonably likely to
have a Material Adverse Effect.
(b) The
Business is being and has been conducted in compliance, in all material
respects, with all Permits and applicable Laws.
Section
6.6 Litigation.
There is
no action, proceeding, claim, suit, opposition, challenge, cancellation
proceeding, reexamination, interference proceeding, charge or investigation
(collectively, “Proceedings”)
pending or, to Seller’s and each Shareholder’s knowledge, threatened, that
questions the validity of this Agreement or any Collateral Agreement or any
action taken or to be taken in connection with this Agreement or any Collateral
Agreement. There are no Proceedings pending or, to Seller’s and each
Shareholder’s knowledge, threatened that relate to the Transferred Assets, the
Assumed Liabilities or the Business. There are no outstanding judgments, writs,
injunctions, orders, decrees or settlements that apply, in whole or in part,
to
the Transferred Assets, the Assumed Liabilities or the Business or that restrict
the ownership or use of the Transferred Assets, the Assumed Liabilities or
the
Business in any way.
10
Section
6.7 Assets
Necessary to Business; No Other Agreements.
The
Transferred Assets and the Excluded Assets constitute all of the rights,
properties and assets used or held for use in or necessary for the conduct
or
operation of the Business as presently conducted. Other than the Excluded
Assets, immediately following the Closing, none of Seller or the Shareholders
(or any of their respective Affiliates) will own or lease any rights, properties
or assets which are used or held for use in or necessary for the conduct of
the
Business as presently conducted. Other than the Chicago License Agreement,
the
URL-Xxxxxxxx Agreement and Exclusive Sub-License Agreement, neither Seller
nor
the Shareholders are party to any Contract relating to the Compound. Other
than
the Chicago License Agreement, neither Seller nor the Shareholders are party
to
any Contract with the University of Chicago. Neither Seller nor any Shareholder
has entered into any agreement or arrangement which conflicts with Seller’s
obligations under the Exclusive Sub-License Agreement, the URL-Xxxxxxxx
Agreement or the Chicago License Agreement or that restricts, impairs or renders
conditional the rights granted to Purchaser under the Exclusive Sub-License
Agreement, the URL-Xxxxxxxx Agreement or the Chicago License
Agreement.
Section
6.8 Financial
Statements.
(a) Section 6.8(a)
of the Disclosure Schedule sets forth the unaudited balance sheets, summary
of
operations and statements of unappropriated retained earnings for the Business
as of and for the year ended April 30, 2004 and April 30, 2005 (collectively,
the “Financial
Statements”).
(b) The
balance sheets included in the Financial Statements fairly present in all
material respects the financial position of the Business as of the date thereof
and the summary of operation statements included in the Financial Statements
fairly present in all material respects the financial position and the results
of operations of the Business as of and for the period then ended. The Financial
Statements have been prepared in accordance with the books and records of the
Business consistent with past practice.
Section
6.9 Absence
of Certain Changes.
Since
December 31, 2004, (a) Seller has operated the Business in the ordinary course
of business consistent with past practice and (b) there has not occurred any
event or condition that, individually or in the aggregate, has had or is
reasonably likely to have a Material Adverse Effect.
Section
6.10 No
Default.
None of
Seller or the Shareholders have committed, or received notice of, any default
or
violation (and no event has occurred which with notice or lapse of time or
both
would constitute a default or violation or loss of any material benefit) of
any
term, condition or provision of (a) any Contract to which Seller or any
Shareholder is a party or may be subject that is included in the Transferred
Assets or the Assumed Liabilities or otherwise relates to or affects the
Business or (b) any order, writ, injunction, decree, statute, treaty, rule
or
regulation applicable to the Business or any of the Transferred Assets or the
Assumed Liabilities.
11
Section
6.11 Contracts.
(a) Section 6.11(a)
of the Disclosure Schedule sets forth a complete and accurate list of all
material Contracts relating to the Business and any Contract relating to the
Compound.
(b) Section
6.11(b) of the Disclosure Schedule sets forth a complete and accurate list
of
all Contracts requiring consent to the assignment thereof to Purchaser
(individually, a “Contract
Requiring Consent”
and
collectively, the “Contracts
Requiring Consent”).
(c) (i)
Each
Contract included in the Transferred Assets or the Assumed Liabilities is legal,
valid, binding and enforceable against Seller or any of the Shareholders party
thereto, as the case may be, and to Seller’s and each Shareholder’s knowledge,
against each other party thereto, is in full force and effect and will continue
to be so legal, valid, binding and enforceable and in full force and effect
following the assignment of such Contract at the Closing, and (ii) none of
Seller or any of the Shareholders and, to Seller’s and each Shareholder’s
knowledge, no other party, is in breach or default, and no event has occurred
which would constitute (with or without notice or lapse of time or both) a
breach or default (or give rise to any right of termination, modification,
cancellation or acceleration) or loss of any benefits under any such Contract,
except in each case as would not, individually or in the aggregate, be
reasonably likely to have a Material Adverse Effect.
(d) Seller
has delivered to Parent complete and accurate copies of each Contract, or where
they are oral, complete and accurate written summaries thereof, listed in
Section 6.11(a) of the Disclosure Schedule. Since December 31, 2004, there
has been no material modification, waiver, breach or termination of any such
Contract or any material provision thereto. To the knowledge of Seller and
each
Shareholder, no modification, waiver, breach or termination of any Contract
listed in Section 6.11(a) of the Disclosure Schedule is contemplated and no
Contract listed in Section 6.11(a) of the Disclosure Schedule (other than those
so noted in the Disclosure Schedule) is terminable or cancelable as a result
of
the consummation of the transactions contemplated in this
Agreement.
(e) There
are
no non-competition or non-solicitation agreements or any similar agreements
or
arrangements that would restrict or hinder the operation or conduct of the
Business or use of any of the Transferred Assets or any “earn-out” agreements or
arrangements to which Seller or any Shareholder is a party or to which Seller,
any Shareholder, the Business or the Transferred Assets is or may be subject
(other than this Agreement or pursuant to this Agreement).
Section
6.12 Employees.
Seller
does not have any employees.
12
Section
6.13 Title
to Assets.
Seller
is the sole owner or exclusive licensee of, or has the right to use, and has
good, valid and marketable title to, the Transferred Assets free and clear
of
any Liens (other than Permitted Liens).
Section
6.14 Assignment
of Contracts.
No
provision of any Contract, arrangement, understanding or Law or other item
which
binds or may bind the Business or is included in the Transferred Assets or
the
Assumed Liabilities, prevents, materially hinders or would prevent or materially
hinder the Business from assigning the Assumed Contracts or arrangements, other
than any necessary consent listed on Schedule 6.11(b).
Section
6.15 Environmental.
(i)
Except as would not, individually or in the aggregate, be reasonably likely
to
have a Material Adverse Effect, there has been no Release or threatened Release
of any Hazardous Substance from, onto or under any of the properties (including,
without limitation, soils, groundwater, surface water, buildings or other
structures) currently or formerly owned, leased or operated by Seller or the
Business, and (ii) Seller has provided to Parent copies of all material reports
in the possession of Seller, including, without limitation, “Phase I,” “Phase
II,” “environmental assessment” and similar reports, relating to the
environmental condition of the Business or the Transferred Assets or the
compliance of Seller, the Business or the Transferred Assets with Environmental
Laws.
Section
6.16 No
Broker.
No
agent, broker, investment banker, financial advisor or other firm or Person
is
or will be entitled to any broker’s or finder’s fee or any other commission or
similar fee payable by Seller or any Shareholder in connection with any of
the
transactions contemplated by this Agreement.
Section
6.17 No
Misleading Statements.
The
representations and warranties made by Seller and the Shareholders in this
Agreement, including, without limitation, the exhibits and schedules hereto,
do
not include any untrue statement of a material fact or omit to state any
material fact.
Section
6.18 Employee
Benefits.
Since
December 31, 2004, the Seller has not had any Benefit Plans or been party to
or
participated in any Benefit Plans.
13
Section
6.19 Taxes.
(a) All
Tax
Returns required to be filed and relating in any manner to any of the
Transferred Assets or the Business have been timely filed. All such Tax Returns
(i) were prepared in the manner required by applicable Law and (ii) are true,
correct and complete in all material respects.
(b) Seller
has paid, or caused to be paid, all Taxes due with respect to any of the
Transferred Assets or the Business whether or not shown (or required to be
shown) on a Tax Return.
(c) There
has
been no notice of a deficiency or assessment or other claim relating in any
manner to any of the Transferred Assets or the Business from any Taxing
Authority which has not been fully paid or finally settled. There are no current
audits or examinations of, and no notice of audit or examination of, any Tax
Return that relates to any of the Transferred Assets or the Business. Seller
has
not given nor has there been given on Seller’s behalf a waiver or extension of
any statute of limitations relating to the payment of Taxes relating to any
of
the Transferred Assets or the Business.
(d) Seller
has complied with all applicable Laws, rules and regulations relating to the
withholding of Taxes and the payment thereof to the appropriate Taxing
Authority, including, without limitation, Taxes required to have been withheld
and paid in connection with amounts paid or owing to any employee or independent
contractor.
(e) No
claim
has ever been made by any Taxing Authority with respect to any of the
Transferred Assets or the Business in a jurisdiction where Seller does not
file
Tax Returns that Seller may be subject to taxation in that
jurisdiction.
(f) There
are
no encumbrances or security interests on any of the Transferred Assets that
arose in connection with any failure (or alleged failure) to pay any Taxes
and,
except for Liens for real and personal property Taxes that are not yet due
and
payable, there are no Liens for any Tax upon any Transferred Asset. Neither
Parent nor Purchaser will be liable for, and none of the Transferred Assets
will
be subject to a Lien with respect to, any Taxes arising out of, relating to
or
in respect of the Business or any of the Transferred Assets for any tax period
or portion thereof ending on or after the Closing Date.
(g) None
of
the Transferred Assets is (i) “tax-exempt use property” within the meaning of
Section 168(h) of the Code, or (ii) “tax-exempt bond financed property” within
the meaning of Section 168(g)(5) of the Code.
(h) The
Transferred Assets do not include any shares of capital stock of, or any other
interest in, any Affiliate of Seller, or any other Person.
14
(i) For
purposes of this Agreement:
(i) “Tax”
and
“Taxes”
mean
any
and
all federal, state, local and foreign taxes, assessments and other governmental
charges, duties, impositions, levies and liabilities, including, without
limitation, taxes based upon, measured by, or with respect to income,
net income, gross income, earnings, profits or gross receipts, or any sales,
use, ad valorem, transfer, franchise, license, withholding, payroll, employment,
excise, severance, stamp, occupation, premium, property, windfall profits,
environmental, alternative, add-on minimum, custom duties, capital stock, social
security (or similar), unemployment, disability, gains,
recapture, estimated,
or other taxes, fees, assessments or charges of any kind whatsoever, together
with any interest, penalty, and addition thereto. “Taxes” also includes any
liability as a transferee or successor, by contract or otherwise for any item
listed in the previous sentence.
(ii) “Tax
Return”
means
any return, declaration, report, claim, election, notice or information return
or statement or other document (including, without limitation, any related
or
supporting information, schedules, or exhibits) filed or required to be filed
with any federal, state, local or foreign Governmental Authority or other
authority in connection with any Tax or estimated Tax.
Section
6.20 Proprietary
Rights.
(a) To
the
knowledge of the Seller and each Shareholder, the representations, warranties,
agreements and other statements contained in Section 8.1 of the Exclusive
Sublicense Agreement are true and correct as of the date hereof. Exhibit
B
identifies all U.S. and foreign Patent Rights in the possession of Seller or
any
of the Shareholders used in, held for use in, necessary for or otherwise
relating to the Business (including, without limitation, all Patent Rights
that
cover the Compound or any formulation of, process for preparing, intermediates
for preparing, uses of, packaging or means of delivery of the Compound,
collectively, the “Business
Patents”)
by
disclosing as applicable for each such Patent Right: (i) country, (ii) title,
(iii) application number, (iv) application filing date, (v) patent number,
(vi)
patent issue date, (vii) all inventors, (viii) all owners, co-owners and/or
assignees, and (viv) all Liens (other than Permitted Liens) including, without
limitation, exclusive and nonexclusive licenses.
Section
6.21 Ownership.
The
Shareholders directly own all of the issued and outstanding equity securities
of
Seller and all rights, to the extent such rights exist, to purchase or otherwise
receive equity securities of Seller.
Section
6.22 Business.
Since
its inception, Seller has engaged in no activities or operations other than
the
Business.
15
Section
6.23 Entirely
for Own Account.
Seller
and the Shareholders are acquiring the Shares for investment for their own
account, not as nominees or agents, and not with a view to the resale or
distribution of any part thereof, and have no present intention of selling,
granting any participation, or otherwise distributing the Shares, except, with
respect to Seller, as required to effectuate the reorganization contemplated
by
this Agreement.
Section
6.24 Disclosure
of Information.
Seller
has received all the information from Parent and its management that Seller
considers necessary or appropriate for deciding whether to acquire the Shares
hereunder. Seller further represents that it has had an opportunity to ask
questions of Parent regarding Parent’s business, management and financial
affairs and such questions were answered to its satisfaction.
Section
6.25 Investment
Experience and Accredited Investor Status. Each
Shareholder is an accredited investor (as defined in Regulation D promulgated
under the Securities Act) and acknowledges that it is able to fend for itself,
and bear the economic risk of its investment in Parent and has such knowledge
and experience in financial or business matters that it is capable of evaluating
the merits and risks of the investment in the Shares hereunder.
Section
6.26 Restricted
Securities.
Seller
understands that the Shares, when issued, will be restricted securities under
the federal securities laws inasmuch as they are being acquired from Parent
in a
transaction not involving a public offering and that under such laws and
applicable regulations such securities may be resold without registration under
the Securities Act only in certain limited circumstances. In this connection,
Seller represents that it is familiar with Rule 144, as presently in effect,
and
understands the resale limitations imposed thereby and by the Securities
Act.
Section
6.27 Legends.
The
Shares shall not be sold or transferred unless either (i) they first shall
have been registered under the Securities Act, (ii) they are sold pursuant
to
Rule 144 under the Securities Act and, if requested by Parent’s transfer agent,
Parent is furnished with an opinion of legal counsel reasonably satisfactory
to
Parent, to the effect that such sale or transfer is exempt from the registration
requirements of the Securities Act or (iii) Parent first shall have been
furnished with an opinion of legal counsel reasonably satisfactory to Parent,
to
the effect that such sale or transfer is exempt from the registration
requirements of the Securities Act. It is understood that the certificates
evidencing the Shares will bear the following legend:
16
“These
securities have not been registered under the Securities Act of 1933, as
amended. They may not be sold, offered for sale, pledged, hypothecated or
otherwise transferred in the absence of a registration statement in effect
with
respect to the securities under such Act or, if requested, an opinion of counsel
satisfactory to Parent is obtained to the effect that such registration is
not
required.”
Section
6.28 Univertical
Transfer.
(a) The
Assignment and Assumption Agreement (the “Univertical
Assignment”)
by and
among the Seller, Univertical Ria Labs, Incorporated (“Univertical”)
and
the shareholders of Univertical was duly executed by the parties thereto and
delivered to the Parent prior to the date hereof, has not been amended and
is in
full force and effect.
(b) The
Univertical Assignment duly and validly conveyed all assets and liabilities
of
Univertical, including any assets and liabilities conveyed to the shareholders
of Univertical upon the dissolution of Univertical, to the Seller.
(c) At
the
time of execution of the Univertical Assignment no Person other than the
Shareholders owned or controlled directly or indirectly, and no Person other
than the Shareholders, Xxxxxxx Xxxxx and Xxxxxxxxx Xxxxx Xxxxxxx has ever owned
or controlled directly or indirectly, any capital stock or other securities
of,
or any ownership interests in, Univertical.
(d) All
capital stock, securities and ownership interests in Univertical held by Xxxxxxx
Xxxxx were conveyed to The Drell Trust prior to the effective date of the
Univertical Assignment and remain the property of The Drell Trust other than
any
distribution thereof to any of the Shareholders.
ARTICLE
VII
REPRESENTATIONS
AND WARRANTIES OF PARENT AND PURCHASER
Parent
and Purchaser, jointly and severally, represent and warrant to Seller and the
Shareholders as follows:
Section
7.1 Corporate
Organization.
Parent
is a corporation duly incorporated, validly existing and in good standing under
the laws of the State of Delaware. Purchaser is a corporation duly incorporated,
validly existing and in good standing under laws of the State of Nevada. Each
of
Parent and Purchaser has full power and authority to own, lease, operate and
otherwise hold its properties and assets and to carry on its business as
presently conducted. Each of Parent and Purchaser is duly qualified or licensed
to do business as a foreign corporation and is in good standing in every
jurisdiction in which the nature of the business conducted by it or the assets
or properties owned or leased by it requires qualification, except where the
failure to be so qualified, licensed or in good standing would not, individually
or in the aggregate, be reasonably likely to have a Material Adverse
Effect.
17
Section
7.2 Authorization
and Effect of Agreement.
Each of
Parent and Purchaser has the full power and authority to execute and deliver
this Agreement and the Collateral Agreements to which it is a party and to
perform its obligations hereunder and thereunder. The execution and delivery
by
each of Parent and Purchaser of this Agreement and the Collateral Agreements
to
which it is a party and the performance by it of the transactions contemplated
hereby and thereby have been duly authorized by all necessary corporate action
on the part of Parent and Purchaser. This Agreement has been duly executed
and
delivered by each of Parent and Purchaser constitutes a legal, valid and binding
obligation of each of Parent and Purchaser, enforceable against them in
accordance with its terms, subject to applicable bankruptcy, reorganization,
moratorium and similar Laws affecting creditors’ rights and remedies
generally.
Section
7.3 Consents
and Approvals; No Violations.
No
filing with, and no Permit or Consent of any Governmental Authority is necessary
for the consummation by Parent or Purchaser of the transactions contemplated
by
this Agreement and any Collateral Agreements. Neither the execution and delivery
of this Agreement and any Collateral Agreement by each of Parent or Purchaser
nor the consummation by each of Parent or Purchaser of the transactions
contemplated by this Agreement and any Collateral Agreements to which it is
a
party, nor compliance by Parent or Purchaser with any of the provisions hereof
or thereof will (a) conflict with or result in any breach of any provision
of
their respective certificates of incorporation or by-laws, (b) result in a
violation or breach of, or constitute (with or without due notice or lapse
of
time or both) a default (or give rise to any right of termination, cancellation
or acceleration or loss of material benefits) under, any of the terms,
conditions or provisions of any Contract to which Parent or Purchaser is a
party
or by which either Parent or Purchaser or any of their properties or assets
may
be bound or (c) violate any order, writ, injunction, decree, statute, treaty,
rule or regulation applicable to Parent or Purchaser, or any of their properties
or assets, except in the case of clauses (b) or (c) for violations, breaches
or
defaults which would not, in the aggregate, prevent or materially delay the
consummation of the transactions contemplated by this Agreement.
Section
7.4 No
Broker.
No
agent, broker, investment banker, financial advisor or other firm or Person
is
or will be entitled to any broker’s or finder’s fee or any other commission or
similar fee in connection with any of the transactions contemplated by this
Agreement.
18
Section
7.5 SEC
Reports.
Since
January 1, 2003, Parent has filed all required reports, schedules, forms,
statements and other documents with the SEC (the “Parent
SEC Documents”),
except where the failure to file such Parent SEC Documents would not,
individually or in the aggregate, have a material adverse effect on the
business, operations, assets, liabilities, condition (financial or otherwise),
results of operations of Parent or the timely consummation of the transactions
contemplated by this Agreement. As of their respective dates, the Parent SEC
Documents complied as to form in all material respects with the requirements
of
the Securities Act or the Securities Exchange Act, as the case may be, and
the
rules and regulations of the SEC promulgated thereunder applicable to such
Parent SEC Documents, and no Parent SEC Documents when filed contained any
untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein,
in
light of the circumstances under which they were made, not misleading.
Section
7.6 Financial
Statements.
Parent
made available to Seller (i) Parent’s audited financial statements for the year
ended December 31, 2004 contained in Parent’s annual report on Form 10-K (the
“Audited
Financial Statements”);
and
(ii) Parent’s unaudited financial statements for the quarter ended March 31,
2005, the quarter ended June 30, 2005 and the quarter ended September 30, 2005
contained in Parent’s quarterly reports on Form 10-Q (collectively with the
Audited Financial Statements, “Parent
Financial Statements”).
Parent Financial Statements have been prepared in accordance with generally
accepted accounting principles (“GAAP”)
applied on a consistent basis throughout the periods indicated (except as may
be
indicated in such Parent Financial Statements or the notes thereto or as
permitted by Form 10-Q) and fairly present in all material respects the
financial condition and operating results of Parent as of the dates, and for
the
periods, indicated therein (subject, in the case of unaudited statements, to
normal year-end audit adjustments).
Section
7.7 Parent
Common Stock.
When
issued to Seller as the Purchase Price in accordance with the terms hereof,
the
Shares will be duly authorized, validly issued, fully paid and nonassessable.
19
ARTICLE VIII
COVENANTS
Section
8.1 Access.
Seller
shall, and the Shareholders shall cause Seller to, afford to officers,
employees, accountants, counsel and other representatives of Parent reasonable
access to all of the assets, properties, personnel, books and records of Seller
relating to the Business, the Transferred Assets and the Assumed
Liabilities.
Section
8.2 Notification.
Seller
and the Shareholder Designee shall promptly notify Parent, and Parent shall
promptly notify Seller and the Shareholder Designee, of any litigation,
arbitration or administrative proceeding (including, without limitation,
interference proceedings and reexaminations) pending or, to their knowledge,
threatened against Seller, any of the Shareholders, Purchaser or Parent, as
the
case may be, which challenges the transactions contemplated by this Agreement
or
any Collateral Agreement.
Section
8.3 No
Inconsistent Action.
None of
Purchaser, Parent, Seller or any of the Shareholders will take any action which
is inconsistent with its respective obligations under this
Agreement.
Section
8.4 Further
Assurances.
From
time to time after the Closing, without additional consideration, each party
hereto will (or, if appropriate, cause its Affiliates to) execute and deliver
such further instruments and take such other action as may be necessary or
reasonably requested by the other party to make effective the transactions
contemplated by this Agreement and the Collateral Agreements and to provide
the
other party with the intended benefits of this Agreement and the Collateral
Agreements. Without limiting the foregoing, upon reasonable request of Parent
or
Purchaser, Seller shall, the Shareholders shall cause Seller to, and Seller
and
the Shareholders shall cause their respective Affiliates to, as applicable,
execute, acknowledge and deliver all such further assurances, deeds,
assignments, consequences, powers of attorney and other instruments and paper
as
may be required to sell, transfer, assign, convey and deliver to Purchaser
all
right, title and interest in, to and under the Transferred Assets. If any party
to this Agreement shall, following the Closing, have in its possession any
asset
or right (including, without limitation, with respect to any Proprietary Rights)
which under this Agreement should have been delivered to the others, such party
shall promptly deliver such asset or right to the others.
20
Section
8.5 Transfer
Taxes.
Notwithstanding any other provision of this Agreement, all transfer,
registration, stamp, documentary, sales, use and similar taxes, and any
penalties, interest and additions to tax, incurred in connection with this
Agreement or the transfer of the Business and the Transferred Assets shall
be
the responsibility of and be timely paid by Seller. Seller, the Shareholders
and
Parent shall cooperate in the timely making of all filings, returns, reports
and
forms as may be required in connection therewith.
Section
8.6 Bulk
Sales Laws.
The
parties hereto hereby waive compliance with the provisions of any applicable
bulk sales laws, including, without limitation, Article 6 of the Uniform
Commercial Code as it may be in effect in any applicable jurisdiction
(“Bulk
Sales Laws”).
This
provision shall not be deemed to in any way limit the indemnity provided for
in
Article
IX
hereto.
Section
8.7 Confidentiality.
The
parties hereto agree that all information shall be kept confidential in
accordance with the terms of the Confidentiality Agreement, dated as of October
17, 2005, between Parent and Seller.
Section
8.8 Non-Competition.
From the
Closing and for a period of three (3) years thereafter, the Seller and the
Shareholders shall not, and shall cause their Affiliates not to, directly or
indirectly, lend funds to, or provide any management, consulting, financial,
administrative or other services to, or own any interest or invest in, any
business engaged in developing, licensing, commercializing or manufacturing
any
pharmaceutical product that competes with pharmaceutical products or product
candidates containing the Compound as an active ingredient developed or
commercialized by Parent, Purchaser or any other Affiliate of Parent.
Section
8.9 Market
Listing.
Parent
shall use commercially reasonable efforts to effect the listing of the Shares
on
the NASDAQ National Market.
Section
8.10 Certain
Agreements. Seller
and the Shareholders acknowledge that, as of the date hereof, Parent is current
in all payment obligations required by the Exclusive Sub-License Agreement,
and
each of Seller and the Shareholders irrevocably waive any claims to the
contrary. Seller and each of the Shareholders irrevocably waive any claims
that,
prior to the date hereof, Parent failed to satisfy any of the diligence
requirements set forth in Article 4 of the Exclusive Sub-License Agreement.
Seller and each of the Shareholders irrevocably waive any claims that, prior
to
the date hereof, Parent failed to fulfill any of its obligations under the
Exclusive Sub-License Agreement, or otherwise failed to comply with the terms
and conditions of the Exclusive Sub-License Agreement.
21
Section
8.11 Covenant
to Provide Legal Opinions.
With
respect to the Shares, Parent covenants and agrees that at such time(s) that
such shares (or any portion thereof) are sold pursuant to Rule 144 under the
Securities Act, if requested by Parent’s transfer agent, Parent shall furnish
(or cause to be furnished) to its transfer agent an opinion of legal counsel,
to
the effect that such sale or transfer is exempt from the registration
requirements of the Securities Act; provided that Parent shall have received
from the Seller or the Shareholders, as applicable, customary documentation
relating to such sale or transfer, including a seller’s representation letter, a
broker’s representation letter and completed Form 144.
Section
8.12 Certain
Tax Matters.
Neither
Parent nor Purchaser will knowingly take any position on any Tax Return that
is
inconsistent with the transaction described in this Agreement qualifying as
a
“reorganization” within the meaning of Section 368(a)(1)(C) of the
Code.
ARTICLE
IX
SURVIVAL;
INDEMNIFICATION
Section
9.1 Survival
of Indemnification Rights.
Subject
to the limitations and other provisions of this Agreement, the representations
and warranties of Seller and the Shareholders contained in Article
VI
hereto
shall survive the Closing and remain in full force and effect for a period
of
sixteen (16) months following the Closing Date and, if a claims notice has
been
provided by such date, shall remain in full force and effect until final
resolution thereof; provided
that (i)
the representations and warranties contained in Section 6.19
(Taxes)
shall survive and remain in full force and effect until sixty (60) calendar
days
after the expiration of the applicable statute of limitations (including any
extension thereof) and (ii) any representation or warranty that is fraudulently
given shall remain in full force and effect indefinitely. The covenants and
agreements of Seller and the Shareholders contained in this Agreement shall
survive and remain in full force and effect for the applicable period specified
therein, or if no such period is specified, indefinitely. None of the Closing,
Parent’s waiver of any condition to the Closing or Parent’s knowledge of any
breach prior to the Closing, shall constitute a waiver of any of the rights
Parent may have hereunder.
22
Section
9.2 Indemnification
Obligations.
Provided
that a notice of claim is delivered in accordance with Section
9.3(a),
Seller
and the Shareholders shall jointly and severally indemnify, defend and hold
harmless Parent, Purchaser and any subsidiary, associate, Affiliate, director,
officer, stockholder or agent of Purchaser or Parent, and their respective
representatives, successors and permitted assigns (all of the foregoing are
collectively referred to as the “Purchaser
Indemnified Parties”)
from
and against and pay on behalf of or reimburse such party in respect of, as
and
when incurred, all out-of-pocket losses, liabilities, demands, claims, actions
or causes of action, costs, damages, judgments, debts, settlements, assessments,
deficiencies, Taxes, penalties, fines or expenses, whether or not arising out
of
any claims by or on behalf of a third party, including, without limitation,
interest, penalties, reasonable attorneys’ fees and expenses and all reasonable
amounts paid in investigation, defense or settlement of any of the foregoing
(collectively, “Losses”)
which
any such party may suffer, sustain or become subject to, as a result of, in
connection with, or relating to or by virtue of:
(a) any
inaccuracy in, or breach of, any representation or warranty made by Seller
or
any of the Shareholders under this Agreement or any Collateral Agreement;
(b) any
material breach or non-fulfillment of any covenant or agreement on the part
of
Seller or any of the Shareholders under this Agreement or any other Collateral
Agreement;
(c) the
ownership or operation of the Transferred Assets or the conduct or operation
of
the Business or the activities of Seller or any of the Shareholders in
connection with the Transferred Assets or the Business on or prior to the
Closing Date;
(d) any
applicable Bulk Sales Laws as a result of the actions contemplated by
Section
8.6
hereto;
(e) any
fees,
expenses or other payments incurred or owed by Seller or any of the Shareholders
to any agent, broker, investment banker or other firm or Person retained or
employed in connection with the transactions contemplated by this Agreement;
(f) the
Retained Liabilities;
(g) any
disputes among the shareholders and former shareholders of the Seller or
Univertical and their estates, heirs, beneficiaries or others relating to the
allocation or distribution of the Purchase Price; or
23
Section
9.3 Indemnification
Procedure.
(a) If
any
Purchaser Indemnified Party intends to seek indemnification pursuant to this
Article
IX,
such
Purchaser Indemnified Party shall promptly notify Seller and the Shareholders
(the “Indemnifying
Parties”),
in
the case of the Shareholders by delivering notice to the Shareholder Designee,
in writing of such claim. The Purchaser Indemnified Party will provide the
Indemnifying Parties, in the case of the Shareholders by delivering notice
to
the Shareholder Designee, with prompt notice of any third party claim in respect
of which indemnification is sought. The failure to provide either such notice
will not affect any rights hereunder except to the extent the Indemnifying
Parties are materially prejudiced thereby.
(b) If
such
claim involves a claim by a third party against the Purchaser Indemnified
Parties, the Indemnifying Parties may, within thirty (30) calendar days after
receipt of such notice and upon notice to the Purchaser Indemnified Parties,
assume, through counsel of their own choosing and at their own expense, the
settlement or defense thereof, and the Purchaser Indemnified Parties shall
reasonably cooperate with them in connection therewith; provided
that the
Purchaser Indemnified Parties may participate in such settlement or defense
through counsel chosen by it; provided further
that if
the Purchaser Indemnified Parties reasonably determine that representation
by
the Indemnifying Parties’ counsel of the Indemnifying Parties and the Purchaser
Indemnified Parties may present such counsel with a conflict of interests,
then
the Indemnifying Parties shall pay the reasonable fees and expenses of the
Purchaser Indemnified Parties’ counsel. Notwithstanding anything in this
Section 9.3
to the
contrary, no Indemnifying Parties may, without the prior written consent of
the
Purchaser Indemnified Parties, settle or compromise any action or consent to
the
entry of any judgment, such consent not to be unreasonably withheld. So long
as
the Indemnifying Parties are contesting any such claim in good faith, the
Purchaser Indemnified Parties shall not pay or settle any such claim without
the
Indemnifying Parties’ consent, such consent not to be unreasonably withheld. If
the Indemnifying Parties are not contesting such claim in good faith, then
the
Purchaser Indemnified Parties may conduct and control, through counsel of their
own choosing and at the expense of the Indemnifying Parties, the settlement
or
defense thereof, and the Indemnifying Parties shall cooperate with it in
connection therewith. The failure of the Purchaser Indemnified Parties to
participate in, conduct or control such defense shall not relieve the
Indemnifying Parties of any obligation it may have hereunder.
Section
9.4 Tax
Treatment of Indemnification.
For all
Tax purposes, the parties hereto agree to treat (and shall cause each of their
respective Affiliates to treat) any indemnity payment under this Agreement
as an
adjustment to the Purchase Price.
24
Section
9.5 Relation
of Indemnity to Escrow Shares.
The
Escrow Agent shall release to the Purchaser Indemnified Parties an amount of
Escrow Shares such that the value of the released Escrow shares is equal to
any
amount that is owed hereunder by the Indemnifying Parties to any Purchaser
Indemnified Party at such time in accordance with the terms of the Escrow
Agreement. Such Escrow Shares shall be valued at the last reported sales price
of the Common Stock as of the end of regular trading hours as reported on the
NASDAQ National Market, NASDAQ Capital Market or any other national securities
exchange or nationally recognized trading system on which the Common Stock
is
then listed or approved for quotation on the day immediately preceding the
day
such Escrow Shares are delivered to the Purchaser Indemnified Party by the
Escrow Agent or if not so listed or approved for quotation, at the fair market
value as determined by an independent valuation firm appointed by Parent. The
rights of any Purchaser Indemnified Party under the preceding sentence are
in
addition to any other rights and remedies that such Purchaser Indemnified Party
may have under this Agreement.
Section
9.6 Aggregate
Indemnification Liability.
Notwithstanding any provision of this Agreement to the contrary, the aggregate
indemnification liability of Seller and/or the Shareholders under this Agreement
for a claim made pursuant to Section
9.2(a)
properly
and timely brought by Parent and/or Purchaser (including, without limitation,
the provision of notice in accordance with the provisions of Section
10.1(b)
below)
shall not exceed the value of the Escrow Shares as of the Closing Date. The
foregoing limitation on indemnification liability shall not be applicable for
claims brought by Parent and/or Purchaser for a breach of Sections
6.11 (Contracts), 6.13 (Title), 6.15 (Environmental), 6.19 (Taxes), 6.20
(Proprietary Rights), 6.21 (Owership) or 6.28 (Univertical Transfer) of this
Agreement.
ARTICLE
X
MISCELLANEOUS
PROVISIONS
Section
10.1 Notices.
All
notices and other communications required or permitted hereunder will be in
writing and, unless otherwise provided in this Agreement, will be deemed to
have
been duly given when delivered in person or when dispatched by electronic
facsimile transfer (confirmed in writing by mail simultaneously dispatched)
or
one (1) Business Day after having been dispatched by a nationally recognized
overnight courier service to the appropriate party at the address specified
below:
25
(a) If
to
Parent or Purchaser, to:
Progenics
Pharmaceuticals, Inc.
000
Xxx
Xxx Xxxx Xxxxx Xxxx
Xxxxxxxxx,
Xxx Xxxx 00000
Telecopy:
000-000-0000
Attention:
Xxxx X. Xxxxx, Senior Vice President and General Counsel
with
a
copy (which shall not constitute notice) to:
Xxxxx
Xxxxxxxxxx LLP
0000
Xxxxxx xx xxx Xxxxxxxx
Xxx
Xxxx,
Xxx Xxxx 00000
Telecopy:
000-000-0000
Attention:
Xxxxxx Xxxxxx
(b) If
to
Seller and, following dissolution of the Seller, to the Shareholder Designee,
or
the Shareholders, to:
UR
Labs,
Inc.
0000
Xxxxx Xxxxx
Xxxxxx
Xxxx, Xxxxxx 00000
Attention:
Xxxx X. Xxxxx
with
a
copy (which shall not constitute notice) to:
Xxxx
Xxxx
Peek Xxxxxxxx and Xxxxxx
0000
Xxxxxxx Xxxx, Xxxxxx Xxxxx
Xxxx,
Xxxxxx 00000
Telecopy:
775/786-6179
Attention:
Xxxxx Xxxxxx
or
to
such other address or addresses as any such party may from time to time
designate as to itself by like notice.
Section
10.2 Expenses.
Except
as otherwise expressly provided herein, each party hereto will pay any expenses
incurred by it incident to this Agreement and in preparing to consummate and
consummating the transactions provided for herein.
26
Section
10.3 Successors
and Assigns.
No party
to this Agreement may assign any of its rights under this Agreement without
the
prior written consent of the other parties hereto. Subject to the preceding
sentence, this Agreement will apply to, be binding in all respects upon, and
inure to the benefit of the successors and permitted assigns of the parties
hereto. Nothing expressed or referred to in this Agreement will be construed
to
give any Person other than the parties to this Agreement any legal or equitable
right, remedy or claim under or with respect to this Agreement or any provision
of this Agreement. This Agreement and all of its provisions and conditions
are
for the sole and exclusive benefit of the parties to this Agreement and their
successors and assigns.
Section
10.4 Extension;
Waiver.
Any
party hereto may, by written notice to the other parties hereto (in the case
of
the Shareholders, by delivery of written notice to or by the Shareholder
Designee) (a) extend the time for performance of any of the obligations of
the
other party under this Agreement, (b) waive any inaccuracies in the
representations or warranties of the other party contained in this Agreement,
(c) waive compliance with any of the conditions or covenants of the other party
contained in this Agreement or (d) waive or modify performance of any of the
obligations of the other party under this Agreement; provided
that no
such party hereto may, without the prior written consent of the other parties
hereto, make or grant such extension of time, waiver of inaccuracies or
compliance or waiver or modification of performance with respect to its
representations, warranties, conditions or covenants hereunder. Except as
provided in the immediately preceding sentence, no action taken pursuant to
this
Agreement will be deemed to constitute a waiver of compliance with any
representations, warranties, conditions or covenants contained in this Agreement
and will not operate or be construed as a waiver of any subsequent breach,
whether of a similar or dissimilar nature.
Section
10.5 Entire
Agreement.
This
Agreement, which includes the schedules and exhibits hereto, supersedes any
other agreement, whether written or oral, that may have been made or entered
into by any party relating to the matters contemplated by this Agreement and
constitutes the entire agreement by and among the parties hereto.
Section
10.6 Amendments,
Supplements, Etc.
This
Agreement may be amended or supplemented at any time by additional written
agreements as may mutually be determined by Parent, Seller and the Shareholders
to be necessary, desirable or expedient to further the purposes of this
Agreement or to clarify the intention of the parties hereto.
27
Section
10.7 Applicable
Law; Waiver of Jury Trial.
This
Agreement shall be governed by and construed under the laws of the State of
Nevada (without regard to the conflict of law principles thereof). Each of
the
parties hereto irrevocably agrees that any legal action or proceeding with
respect to this Agreement or for recognition and enforcement of any judgment
in
respect hereof shall be brought and determined in any federal or state court
located within Washoe County, Nevada. Each of the parties hereto hereby (a)
irrevocably submits with regard to any such action or proceeding to the
exclusive personal jurisdiction of the aforesaid courts in the event any dispute
arises out of this Agreement or any transaction contemplated hereby and waives
the defense of sovereign immunity, (b) agrees that it shall not attempt to
deny
or defeat such personal jurisdiction by motion or other request for leave from
any such court or that such action is brought in an inconvenient forum and
(c)
agrees that it shall not bring any action relating to this Agreement or any
transaction contemplated hereby in any court other than any Nevada state or
federal court sitting in Washoe County, Nevada. Each of the parties hereby
irrevocably waives trial by jury in any action to which they are parties
involving, directly or indirectly, any matter in any way arising out of, related
to or connected with this Agreement and the transactions contemplated hereby
and
thereby.
Section
10.8 Actions
by Seller or the Shareholders.
Where
any provision of this Agreement indicates that Seller or the Shareholders will
take any specified action (or refrain from taking any specified action) or
requires Seller or the Shareholders to take any specified action (or to refrain
from taking any specified action), then, regardless of whether this Agreement
specifically provides that the Shareholders will do so, the Shareholders shall
cause Seller to take such action (or to refrain from taking such action, as
applicable). The Shareholders will be responsible for the failure of Seller
to
take any such action (or to refrain from taking any such action, as
applicable).
Section
10.9 Execution
in Counterparts.
This
Agreement may be executed in two (2) or more counterparts, each of which will
be
deemed an original, but all of which together will constitute one (1) and the
same agreement. Facsimile and/or electronically delivered signatures to this
Agreement and all Collateral Agreements executed in connection herewith shall
be
binding on the parties to this Agreement.
Section
10.10 Titles
and Headings.
Titles
and headings to sections herein are inserted for convenience of reference only,
and are not intended to be a part of or to affect the meaning or interpretation
of this Agreement.
28
Section
10.11 Invalid
Provisions.
If any
provision of this Agreement is held to be illegal, invalid or unenforceable
under any present or future Law, and if the rights or obligations under this
Agreement of Seller on the one hand and Parent on the other hand will not be
materially and adversely affected thereby, (a) such provision will be fully
severable, (b) this Agreement will be construed and enforced as if such illegal,
invalid, or unenforceable provision had never comprised a part hereof, (c)
the
remaining provisions of this Agreement will remain in full force and effect
and
will not be affected by the illegal, invalid, or unenforceable provision or
by
its severance from this Agreement and (d) in lieu of such illegal, invalid
or
unenforceable provision, there will be added automatically as a part of this
Agreement a legal, valid and enforceable provision as similar in terms to such
illegal, invalid or unenforceable provision as may be possible.
Section
10.12 Publicity.
Except
as otherwise required by applicable Law or the rules and regulations of any
national securities exchange, no party hereto shall issue any press release
or
otherwise make any public statement with respect to the transactions
contemplated by this Agreement or the Collateral Agreements without prior
consultation with and consent of the other parties hereto, which consent shall
not be unreasonably withheld, conditioned or delayed.
Section
10.13 Specific
Performance.
The
parties hereto agree that if any of the provisions of this Agreement were not
performed in accordance with their specific terms or were otherwise breached,
irreparable damage would occur, no adequate remedy at law would exist and
damages would be difficult to determine, and that the parties hereto shall
be
entitled to specific performance of the terms hereof, in addition to any other
remedy at law or equity.
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]
29
IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day
and year first above written.
PROGENICS
PHARMACEUTICALS, INC.
By:
Name: Xxxx
X.
Xxxxx
Title: Senior
Vice President and
General
Counsel
PROGENICS
PHARMACEUTICALS NEVADA, INC.
By:
Name:
Xxxx
X.
Xxxxx
Title: Secretary
UR
LABS,
INC.
By:
Name:
Title:
SHAREHOLDERS:
Drell
Family Trust U/A dated 4/28/88
Xxxxx
Xxxxx, Trustee
Xxxx
X.
Xxxxx
Xxxxx
X.
Xxxxx
EXHIBIT
A
DEFINITIONS
AND DEFINED TERMS
(a) As
used
in this Agreement, the following terms shall have the following
meanings:
“Affiliate”
shall
mean with respect to any Person, any other Person who, directly or indirectly,
controls, is controlled by or is under common control with that Person. For
purposes of this definition, a Person has control of another Person if it has
the direct or indirect ability or power to direct or cause the direction of
management policies of such other Person or otherwise direct the affairs of
such
other Person, whether through ownership of at least fifty percent (50%) of
the
voting securities of such other Person, by Contract or otherwise.
“Benefit
Plans”
shall
mean “employee pension benefit plans” (as defined in Section 3(2) of the
Employee Retirement Income Security Act of 1974, as amended (“ERISA”)),
“employee welfare benefit plans” (as defined in Section 3(1) of ERISA), any
bonus, deferred compensation, stock bonus, stock purchase, restricted stock,
stock option, employment, termination, change in control, retention, consulting,
severance or other employee or fringe benefit plans, programs, policies,
arrangements and contracts.
“Business
Day”
shall
mean a day other than a Saturday, Sunday or other day on which commercial banks
in Nevada are authorized or required by law to close.
“Chicago
License Agreement”
shall
mean the Option and License Agreement, dated May 8, 1985, by and between The
University of Chicago and Seller, as amended by the Amendment to Option and
License Agreement, dated September 17, 1987, by and between The University
of
Chicago and Seller and the Second Amendment to Option and License Agreement,
dated March 3, 1989, by and between The University of Chicago, Arch Development
Corporation and Seller, as thereafter may be amended.
“Code”
shall
mean the Internal Revenue Code of 1986, as amended.
“Collateral
Agreements”
shall
mean the Escrow Agreement, Xxxx of Sale, the Assignment and Assumption
Agreement, Chicago License Assignment Agreement, URL-Xxxxxxxx Consent and
Assignment Agreement, PGNX-URL Consent and Assignment Agreement and the other
assignment or transfer documents delivered at the Closing.
“Compound”
means
any and all quarternary derivatives of noroxymorphone including in particular
N-methylnaltrexone having the chemical structure C21H26BrNO4.
“Consent”
shall
mean any consent, approval or authorization of, notice to, or designation,
registration, declaration or filing with, any Person.
A1
“Contract”
shall
mean any note, bond, mortgage, indenture, contract, agreement, permit, license,
lease, purchase order, sales order, arrangement or other commitment, obligation
or understanding, written or oral, to which a Person is a party or by which
a
Person or its assets or properties are bound.
“Environmental
Law”
shall
mean any Law relating to the protection, investigation or restoration of the
environment (including, without limitation, natural resources) or the health
or
safety of human or other living organisms, including, without limitation, the
manufacture, introduction into commerce, export, import, handling, use,
presence, disposal, Release or threatened Release of any Hazardous Substance.
“Exclusive
Sub-License Agreement”
shall
mean the Exclusive Sublicense Agreement by and between Seller and Parent, dated
September 21, 2001.
“Xxxxxxxx
Distributees”
shall
mean Xxxxxxx Xxxxx, Dr. Xxxx Xxxxxxxx and The Xxxxxxx Otee Trust.
“Governmental
Authority”
shall
mean any federal, state, local or foreign government or any subdivision, agency,
instrumentality, authority, department, commission, board or bureau thereof
or
any federal, state, local or foreign court, tribunal or arbitrator.
“Hazardous
Substance”
shall
mean any element, compound, substance or other material (including, without
limitation, any pollutant, contaminant, hazardous waste, hazardous substance,
chemical substance, or product) that is listed, classified or regulated pursuant
to any Environmental Law, including, without limitation, any petroleum product,
by-product or additive, asbestos, presumed asbestos-containing material,
asbestos-containing material, medical waste, lead-containing paint or plumbing,
polychlorinated biphenyls, radioactive material or radon.
“Know
How”
means
all technology and information, including, without limitation, methods,
processes, techniques, compounds, drawings, indications, data, results of tests
or studies (including clinical studies performed with respect to the Compound,
whether performed by or under the auspices of Seller, the Shareholders or the
University), expertise and trade secrets, whether or not patentable, relating
to
the Compound or necessary or useful for the research, development, manufacture
or commercialization of the products containing or consisting of the Compound
which is owned or controlled by Seller and/or the Shareholders or in which
Seller and/or one or more of the Shareholders has a license right.
“knowledge”
shall
mean the knowledge any Person would have after due inquiry.
“Laws”
shall
mean all federal, state, local or foreign laws, orders, writs, injunctions,
decrees, ordinances, awards, stipulations, statutes, judicial or administrative
doctrines, rules or regulations enacted, promulgated, issued or entered by
a
Governmental Authority.
A2
“Liens”
shall
mean all title defects or objections, mortgages, liens, claims, charges, pledges
or other encumbrances of any nature whatsoever, including, without limitation,
licenses, leases, chattel or other mortgages, collateral security arrangements,
pledges, title imperfections, defect or objection liens, security interests,
conditional and installment sales agreements, easements, encroachments or
restrictions, of any kind and other title or interest retention arrangements,
reservations or limitations of any nature.
“Material
Adverse Effect”
shall
mean a material adverse effect on (i) the Transferred Assets or the Assumed
Liabilities or the business, operations, assets, liabilities, condition
(financial or otherwise), results of operations or prospects of the Business
or
(ii) the timely consummation of the transactions contemplated by this
Agreement.
“Patent
Rights”
means
any and all (a) U.S. or foreign patents, (b) U.S. or foreign patent
applications, including, without limitation, all provisional applications,
substitutions, continuations, continuations-in-part, divisions, renewals, and
all patents granted thereon, (c) all U.S. or foreign patents-of-addition,
reissues, reexaminations and extensions or restorations by existing or future
extension or restoration mechanisms, including, without limitation,
supplementary protection certificates or the equivalent thereof, and (d) any
other form of government-issued right substantially similar to any of the
foregoing.
“Permits”
shall
mean all permits, licenses, approvals, franchises, notices and authorizations
issued by any Governmental Authority that are used or held for use in, necessary
or otherwise relate to the ownership, operation or other use of any of the
Business or the Transferred Assets.
“Permitted
Liens”
shall
mean (i) mechanics’, carriers’, workmen’s, repairmen’s or other like Liens
arising or incurred in the ordinary course of business for amounts which are
not
material and not yet due and payable and which secure an obligation that is
an
Assumed Liability, (ii) Liens arising under sales Contracts and equipment leases
with third parties entered into in the ordinary course of business which
constitute Assumed Liabilities in respect of amounts still owing, which Liens
are reflected in the Interim Financial Statements, and (iii) Liens for Taxes
and
other governmental charges that are not due and payable or
delinquent.
“Person”
shall
mean any individual, partnership, joint venture, corporation, trust,
unincorporated organization, Governmental Authority or other
entity.
“Proprietary
Rights”
means,
collectively, any and all rights of the Seller in or to the Compound, including
the Business Patents and the Know How, whether owned, controlled or held as
an
licensee.
“Release”
shall
mean any release, pumping, pouring, emptying, injecting, escaping, leaching,
migrating, dumping, seepage, spill, leak, flow, discharge, disposal or
emission.
A3
“Shareholder
Designee”
shall
mean Xxxx X. Xxxxx.
“Taxing
Authority”
shall
mean any national, provincial, state or local government, or any subdivision,
agency, commission or authority thereof exercising tax regulatory, enforcement,
collection or other authority.
“University”
means
the University of Chicago and its affiliates including, without limitation,
ARCH
Development Corp.
“URL-Xxxxxxxx
Agreement”
shall
mean Amended and Restated Agreement dated as of June 11, 2001 by and between
the
Seller and the Xxxxxxxx Distributees.
A4
(b) Each
of
the following terms is defined in the Section set forth opposite such
term:
Term
|
Section
|
Agreement
|
Preamble
|
Assumed
Contracts
|
2.1
|
Assumed
Liabilities
|
3.1
|
Assignment
and Assumption Agreement
|
5.2(a)(iii)
|
Audited
Financial Statements
|
7.6
|
Azaribine
|
2.2
|
Balance
Sheet
|
2.1(a)
|
Xxxx
of Sale
|
5.2(a)(ii)
|
Bulk
Sales Laws
|
8.9
|
Business
|
Recitals
|
Business
Patents
|
6.20(a)
|
Chicago
License Assignment Agreement
|
5.2(a)(iv)
|
Closing
|
5.1
|
Closing
Date
|
5.1
|
Closing
Date Shares
|
4.1(b)(i)
|
Common
Stock
|
4.1(b)
|
Contract(s)
Requiring Consent
|
6.11(b)
|
Disclosure
Schedule
|
Preamble
Article VI
|
Escrow
Agreement
|
4.2
|
Escrow
Agent
|
4.1(b)(ii)
|
Escrow
Shares
|
4.1(b)(ii)
|
Excluded
Assets
|
2.2
|
Financial
Statements
|
6.8(a)
|
GAAP
|
7.6
|
Xxxxxxxx
Consent and Assignment Agreement
|
5.2(a)(v)
|
Income
Statement
|
2.1(a)
|
Indemnifying
Parties
|
9.3(a)
|
Interim
Financial Statements
|
6.8(a)
|
Losses
|
9.2
|
Parent
|
Preamble
|
Parent
Financial Statements
|
7.6
|
Parent
SEC Documents
|
7.5
|
Proceedings
|
6.6
|
Purchase
Price
|
4.1(b)
|
Purchaser
|
Preamble
|
Purchaser
Indemnified Parties
|
9.2
|
Retained
Liabilities
|
3.2
|
Seller
|
Preamble
|
Shareholder(s)
|
Preamble
|
Shares
|
4.1(b)(ii)
|
URL
Consent and Assignment Agreement
|
5.2(a)(v)
|
Tax(es)
|
6.19(i)(i)
|
Tax
Return
|
6.19(i)(ii)
|
Transferred
Assets
|
2.1
|
Univertical
Assignment
|
6.28(a)
|
Univertical
|
6.28(a)
|
A5
EXHIBIT
B
PATENTS
AND PATENT APPLICATIONS
EXHIBIT
C
ESCROW
AGREEMENT
EXHIBIT
D
FORM
OF
XXXX OF SALE
EXHIBIT
E
FORM
OF
ASSIGNMENT AND ASSUMPTION AGREEMENT
EXHIBIT
F
CHICAGO
LICENSE ASSIGNMENT AGREEMENT
EXHIBIT
G
URL-XXXXXXXX
CONSENT AND ASSIGNMENT AGREEMENT
EXHIBIT
H
PGNX-URL
CONSENT AND ASSIGNMENT AGREEMENT
EXHIBIT
I
PATENT
ASSIGNMENT
EXHIBIT
J
REGISTRATION
RIGHTS AGREEMENT
EXHIBIT
K
CROSS
RELEASE
ANNEX
2.1
BALANCE
SHEETS, STATEMENTS OF UNAPPROPRIATED RETAINED EARNINGS AND SUMMARY OF OPERATIONS
FOR
YEARS
ENDED APRIL 30, 2004 AND APRIL 30, 2005